--- title: "TScan Therapeutics (TCRX) news: reverse split and offering" url: "https://aibio.space/companies/tscan-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TCRX reverse split, offering and layoffs news: TScan Therapeutics asks stockholders to approve a reverse split of up to one-for-fifty." --- TCRX TScan Therapeutics, Inc. NASDAQ · United States # TScan Therapeutics (TCRX) news TCRX reverse split, offering and layoffs news Listings · 2026-10-26 ## [TScan Therapeutics asks stockholders to approve a reverse split of up to one-for-fifty](https://aibio.space/news/tscan-therapeutics-asks-stockholders-approve-reverse-split-up-one/) TScan's board will set the reverse split ratio between one-for-two and one-for-fifty, and stockholders vote on November 20, 2026. Nasdaq's bid price deadline is February 23, 2027, and the stock closed at $0.2379 on October 12, 2026. ## Latest TScan Therapeutics news 1. 2026-09-02 Distress [TScan cuts 75% of staff and pauses phase 3 trial for lack of capital](https://aibio.space/news/tscan-cuts-75-percent-staff-pauses-phase-3-trial-lack-capital/) TScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days. 2. 2025-11-03 Distress [TScan Therapeutics cuts about 30% of workforce, 66 roles, to extend cash runway](https://aibio.space/news/tscan-therapeutics-cuts-about-30-percent-workforce-66-roles-extend/) TScan expects annual cost savings of $45.0 million in 2026 and 2027 and a one-time charge of up to approximately $2.3 million. It says its cash runway now extends into the second half of 2027. 3. 2024-12-26 Financings [TScan Therapeutics agrees to sell $30.0 million of pre-funded warrants to Lynx1](https://aibio.space/news/tscan-therapeutics-agrees-sell-30-0-million-pre-funded-warrants-lynx1/) TScan sold pre-funded warrants for 7,500,000 voting shares at $4.00 each in a registered direct offering to Lynx1 entities, for about $30.0 million gross. It says cash will fund operations into the first quarter of 2027, on assumptions that may prove wrong. ## TScan Therapeutics at a glance - **Ticker**: TCRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $100.2 million ### Related companies - [HCW Biologics](https://aibio.space/companies/hcw-biologics/) NASDAQ: HCWB - [Nuvation Bio](https://aibio.space/companies/nuvation-bio/) NYSE: NUVB - [Halozyme Therapeutics](https://aibio.space/companies/halozyme-therapeutics/) NASDAQ: HALO - [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) NASDAQ: ELOX - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX - [Bio-Path Holdings](https://aibio.space/companies/bio-path/) OTC: BPTH - [Cabaletta Bio](https://aibio.space/companies/cabaletta-bio/) NASDAQ: CABA - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) NASDAQ: KYTX ### Also on NASDAQ - [Ardelyx](https://aibio.space/companies/ardelyx/) ARDX - [Cuprina Holdings (Cayman)](https://aibio.space/companies/cuprina-cayman/) CUPR - [CapsoVision](https://aibio.space/companies/capsovision/) CV - [Clearmind Medicine](https://aibio.space/companies/clearmind-medicine/) CMND - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) PRLD - [Elicio Therapeutics](https://aibio.space/companies/elicio-therapeutics/) ELTX ## TScan Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$10.3 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | | Research and development | [$114.2 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | [$107.3 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | | Net income (loss) | [-$129.8 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | [-$127.5 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | | Cash from operations | [-$135.3 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | [-$110.8 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | | Cash and equivalents | [$152.4 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526345749/) | [$178.7 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | | Short-term investments | | [$111.4 million](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $100.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about TScan Therapeutics Did TScan Therapeutics do a reverse stock split? Our latest story on this, dated Oct 26, 2026: "TScan Therapeutics asks stockholders to approve a reverse split of up to one-for-fifty". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tscan-therapeutics-asks-stockholders-approve-reverse-split-up-one/). Has TScan Therapeutics raised money recently? Our latest story on this, dated Dec 26, 2024: "TScan Therapeutics agrees to sell $30.0 million of pre-funded warrants to Lynx1". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tscan-therapeutics-agrees-sell-30-0-million-pre-funded-warrants-lynx1/). Has TScan Therapeutics cut staff? Our latest story on this, dated Sep 2, 2026: "TScan cuts 75% of staff and pauses phase 3 trial for lack of capital". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tscan-cuts-75-percent-staff-pauses-phase-3-trial-lack-capital/). What is the ticker symbol of TScan Therapeutics? TScan Therapeutics, Inc. trades under the ticker TCRX on NASDAQ. Where is TScan Therapeutics listed? TScan Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of TScan Therapeutics? The SEC Central Index Key (CIK) for TScan Therapeutics, Inc. is 1783328. Its filings are on SEC EDGAR. How many shares does TScan Therapeutics have outstanding? 23,976,942 shares as of 2022-03-04, per the cover page of its 10-K filed 2022-03-09. Which country or territory is TScan Therapeutics listed under? Our directory records TScan Therapeutics, Inc. under United States. What does TScan Therapeutics do? Our directory classifies TScan Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of TScan Therapeutics? The ISIN recorded for TScan Therapeutics, Inc. is US89854M1018. Does aibio.space cover TScan Therapeutics? aibio.space lists TScan Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is TScan Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was TScan Therapeutics's revenue last year? $10.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is TScan Therapeutics profitable? TScan Therapeutics, Inc. reported a net loss of $129.8 million for the fiscal year ended Dec 31, 2025, and used $135.3 million of cash in operations, per its annual report to the SEC. How much does TScan Therapeutics spend on research and development? $114.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: TScan Therapeutics Members talk about TScan Therapeutics (TCRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at TScan Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312526431045/d121298ddef14a.htm) 2. 2026-10-16 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312526424240/d121298dpre14a.htm) 3. 2026-09-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.05,3.01,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/d309786dex991.htm) 4. 2026-08-18 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/d143845d8k.htm) 5. 2026-08-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312526345749/tcrx-20260630.htm) 6. 2026-05-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312526236862/d43301d8k.htm) 7. 2025-11-03 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312525261612/d873161dex991.htm) 8. 2024-12-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312524284669/d594617d424b5.htm) 9. 2024-12-23 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1783328/000119312524283673/d920508dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TCRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-TCRX/). ## SEC filings and registration - **SEC name**: TScan Therapeutics, Inc. - **CIK**: 1783328 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: TCRX (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 830 WINTER STREET, WALTHAM, MA, 02451 - **Phone**: 857-399-9500 - **Shares outstanding**: 23,976,942 as of 2022-03-04 (10-K filed 2022-03-09) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1783328/000119312526424198/d168046d8k.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1783328/000119312526409199/d59998d8k.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/d171735d8k.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1783328/000119312526379343/d309786d8k.htm) filed 2026-09-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1783328/000119312526355664/d143845d8k.htm) filed 2026-08-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1783328/000119312526345749/tcrx-20260630.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1783328/000119312526345732/tcrx-20260812.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/d103234d8k.htm) filed 2026-06-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001783328), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details TScan Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TCRX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: TScan Therapeutics, Inc. - **Ticker**: TCRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US89854M1018 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TCRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tscan-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "TScan Therapeutics (TCRX) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/tscan-therapeutics/